 Monopar Therapeutics Inc. today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full their option to purchase an additional 166,666 shares of common stock. The closing is expected to occur on December 23, 2019, subject to customary closing conditions, bringing the total number of shares sold by Monopar Therapeutics in the initial public offering to 1,277,778 and total gross proceeds to approximately 10.2 million. The total net proceeds, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately 9.3 million from the initial public offering. 